Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 10:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 707 matching trials from the live ClinicalTrials.gov search.
Filters: "mild cognitive impairment" Condition: Alzheimer's Disease Clear all
Recruiting Phase 2 Interventional

Open-label Extension Study in Participants With Early Alzheimer's Disease

NCT07105709
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
GSK4527226
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 85 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Maitland, Florida • Miami, Florida • Stuart, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 13, 2026, 10:22 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Exploring the Utility of [18F]3F4AP for Demyelination Imaging in Controls, Neurodegeneration and Traumatic Brian Injury

NCT04710550
View directory record Official record
Conditions
Brain Injuries, Traumatic, Demyelinating Disorder, Alzheimer Disease
Interventions
F18-3F4AP
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 13, 2026, 10:22 PM EDT
Completed No phase listed Observational

F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction (IND 123119, Protocol E)

NCT02414282
View directory record Official record
Conditions
Alzheimer Disease, Progressive Posterior Cortical Dysfunction (PPCD)
Interventions
F 18 T807
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
45 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 13, 2026, 10:22 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Event-Related Potential (ERP) Components in Clinical Diagnosis

NCT05673759
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Mild, Mild Cognitive Impairment
Interventions
Electroencephalogram (EEG) system, Standard Neuropsychological Testing, Additional neuropsychological tests
Device · Behavioral
Lead sponsor
Boston University
Other
Eligibility
20 Years to 90 Years
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 13, 2026, 10:22 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

NCT06584357
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss, Memory Disorders, Memory Impairment
Interventions
Biomarker Data Collection, MK6240
Other · Radiation
Lead sponsor
GAP Innovations, PBC
Industry
Eligibility
60 Years to 90 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
22
States / cities
Atlantis, Florida • Aventura, Florida • Clermont, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 13, 2026, 10:22 PM EDT
Active, not recruiting Phase 3 Interventional

A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

NCT06709014
View directory record Official record
Conditions
Early Alzheimers Disease
Interventions
buntanetap/posiphen, Placebo
Drug
Lead sponsor
Annovis Bio Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
78
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 13, 2026, 10:22 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Treatment for Early Memory Loss

NCT00042172
View directory record Official record
Conditions
Cognition Disorders, Alzheimer Disease
Interventions
Donepezil, Ginkgo Biloba Extract
Drug
Lead sponsor
University of Iowa
Other
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Oct 13, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.

NCT01436045
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Insulin glulisine, Saline
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
65 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 13, 2026, 10:22 PM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease

NCT00912288
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Dimebon 20 mg po TID, Placebo po TID
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
21
States / cities
Phoenix, Arizona • Costa Mesa, California • Encino, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2012 · Synced Oct 13, 2026, 10:22 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

NCT03131453
View directory record Official record
Conditions
Alzheimers Disease
Interventions
CNP520 50mg, CNP520 15mg, Matching placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years to 75 Years
Enrollment
1,145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
95
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 13, 2026, 10:22 PM EDT
Recruiting Phase 2 Interventional

A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

NCT07589595
View directory record Official record
Conditions
Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
Interventions
Donanemab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 85 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
42
States / cities
Chandler, Arizona • Scottsdale, Arizona • Carlsbad, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 13, 2026, 10:22 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Longitudinal Cognitive Assessment by BoCA

NCT04114994
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Vascular Dementia, Frontotemporal Dementia, Parkinson Disease, Multiple Sclerosis, TBI
Interventions
Boston Cognitive Assessment (BoCA)
Diagnostic Test
Lead sponsor
Alzheimer's Light LLC
Industry
Eligibility
50 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 13, 2026, 10:22 PM EDT
Not listed Not applicable Interventional

Stories in the Moment: Dance Program for People Living With Dementia

NCT06221202
View directory record Official record
Conditions
Dementia, Mild Cognitive Impairment, Alzheimer Disease, Lewy Body Disease, Frontotemporal Dementia, Vascular Dementia
Interventions
Stories in the Moment Dance Program - Online
Other
Lead sponsor
DanceStream Projects
Other
Eligibility
50 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 13, 2026, 10:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility Trial of a Mediterranean Diet Pattern to Prevent Cognitive Decline

NCT02921672
View directory record Official record
Conditions
Alzheimer's Disease, Cognitive Impairment
Interventions
Mediterranean Diet
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
65 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 13, 2026, 10:22 PM EDT
Recruiting Phase 1Phase 2 Interventional

Large-coil Parietal Repetitive Transcranial Magnetic Stimulation (rTMS) for Alzheimer Disease (AD)

NCT06597942
View directory record Official record
Conditions
Alzheimer&Amp;Amp;#39;s Disease, Alzheimer Disease, Dementia Alzheimer Type, Mild Alzheimer&Amp;Amp;#39;s Disease, Moderate Alzheimer&Amp;Amp;#39;s Disease, Alzheimer&Amp;#39;s Disease (AD), Alzheimer&Amp;#39;s Dementia
Interventions
TMS, Transcranial Magnetic Stimulation Sham
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
55 Years to 100 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 13, 2026, 10:22 PM EDT
Not yet recruiting Not applicable Interventional

Jigsawdio Multisensory Platform for People With Mild Cognitive Impairment, Alzheimer's Disease, or Related Dementias

NCT07839286
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Mild Cognitive Impairment
Interventions
Jigsawdio Multisensory Puzzle Platform, Standard Jigsaw Puzzle Activity
Behavioral
Lead sponsor
Callahan-Young LLC DBA Jigsawdio
Industry
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Durham, North Carolina • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 13, 2026, 10:22 PM EDT
Completed Phase 2 Interventional

SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days)

NCT00438568
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Regular Insulin, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
55 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 14, 2012 · Synced Oct 13, 2026, 10:22 PM EDT
Recruiting Phase 1 Interventional

Innate Immunity Stimulation Via TLR9 in Early AD

NCT05606341
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Dementia
Interventions
CpG1018, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 13, 2026, 10:22 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease

NCT00454870
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MEM 3454
Drug
Lead sponsor
Memory Pharmaceuticals
Industry
Eligibility
50 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
7
States / cities
Phoenix, Arizona • Glendale, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated May 6, 2008 · Synced Oct 13, 2026, 10:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Brain Health Study: A Pragmatic, Patient-Centered Trial

NCT05905796
View directory record Official record
Conditions
Dementia, Alzheimer Disease
Interventions
Brain Health Assessment
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
65 Years and older
Enrollment
1,261 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
3
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 13, 2026, 10:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Memory Functions in Mild Alzheimer's Disease

NCT04785053
View directory record Official record
Conditions
Alzheimer Disease
Interventions
transcranial alternating current stimulation (tACS)
Device
Lead sponsor
Hebrew SeniorLife
Other
Eligibility
21 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 13, 2026, 10:22 PM EDT
Recruiting Not applicable Interventional

Time Restricted Eating in Alzheimer's Disease

NCT06429124
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI)
Interventions
Dietary Intervention
Behavioral
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
55 Years to 89 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 13, 2026, 10:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Home-Based Assessment for Alzheimer Disease Prevention

NCT00546767
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Mail and Live Phone, Interactive Voice Response (IVR), Home-based Computer Kiosk, Traditional Evaluation Instruments
Behavioral
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Other
Eligibility
75 Years and older
Enrollment
640 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
28
States / cities
Birmingham, Alabama • Sun City, Arizona • Irvine, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Oct 13, 2026, 10:22 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

NCT02565511
View directory record Official record
Conditions
Alzheimers Disease
Interventions
CAD106 Immunotherapy, Placebo to CAD106, CNP520, Placebo to CNP520, Alum
Biological · Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years to 75 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
78
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 13, 2026, 10:22 PM EDT